Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Monday, August 21, 2017 12:10:51 PM
- Core operations transitioned to phytocannabinoid-based therapies
- Four trial candidates targeting chronic pain, Alzheimer’s and other conditions
- Unique approach combining existing therapies with cannabinoids
India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary alternative medicine (CAM) nutraceutical products. Operating in the world’s fastest growing industry (cannabis) with its novel ‘something old, something new’ approach, IGC could soon expect its valuation to rise in line with peers like Corbus Pharmaceuticals (NASDAQ: CRBP), Anavex Life Sciences (NASDAQ: AVXL) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).
IGC recently disposed of its low-margin iron ore and electronic trading businesses. With that divestment, the company is now focused on its long-term goal of becoming a heavyweight in the cannabis space. To achieve its objective of being a major player of cannabinoid combination therapies, IGC is actively engaged in planning the development pathways for its four product candidates.
IGC-501 heads IGC’s quartet of pipeline candidates. In September 2015, the company filed a Patent Cooperation Treaty (PCT) application for the therapy, which addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. At present, such indications tend to be treated with opioids, which are notoriously addictive. However, the alarming rise and devastating effects of opioid abuse are driving the search for less pernicious alternatives. In the U.S. alone, this presents a market opportunity of around $25 billion.
A PCT filing has also been made for IGC-502, designed to treat canine seizures, which affect about five percent of dogs. Additionally, in August 2016, the company filed for a therapy to treat cachexia, which it has designated IGC-504. Also known as wasting syndrome, cachexia affects about 1.3 million in the U.S. It is a condition that’s typically associated with cancer, multiple sclerosis (MS), Parkinson’s, and HIV/AIDS.
In June 2017, IGC announced it had entered into a definitive agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” This agreement gives IGC a way to enter a huge market for what has been called ‘America’s most expensive disease.’ For 2017, Medicare and Medicaid expenditures for treating Alzheimer’s are expected to reach $175 billion. Currently, over 5.3 million Americans suffer from the condition, and that number is expected to double over the next 20 years.
The drug candidate IGC-ADI explores an alternative way delta 9-tetrahydrocannabinol (THC) interacts with the human body. Several pathways have already been identified, including binding to the CB1 receptor, anti-oxidative effects, and others, but IGC-ADI works through a different molecular pathway that allows low doses of THC to bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which causes the cognitive decline that results in Alzheimer’s disease. If approved, this patent will give IGC a significant proprietary interest in a unique way to treat Alzheimer’s disease. THC is the psychotropic phytocannabinoid mainly responsible for the ‘high’ of cannabis, although, it must be noted, other cannabinoids such as cannabinol (CBN) and tetrahydrocannabivarin (THCV) are psychotropic. The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a Phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.
The same is true of companies developing cannabinoid-based treatments. Corbus Pharmaceuticals, which presently has programs assessing its oral endocannabinoid-mimetic drug candidate for treating a variety of ailments, has a current market cap of around $310 million, and Zynerba, which is also developing synthetic cannabinoids, has a market cap of about $235 million at present. IGC, trading presently at $0.40, has a market cap of about $12 million, a valuation that is unlikely to stay that low for long.
For more information, visit the company’s website at www.IGCInc.us
Recent IGC News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation • Business Wire • 03/20/2024 03:00:00 PM
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 • Business Wire • 03/20/2024 11:00:00 AM
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline • Business Wire • 03/12/2024 07:00:00 PM
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model • Business Wire • 02/28/2024 06:00:00 PM
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target • Business Wire • 02/23/2024 05:01:00 PM
- IGC Pharma Reports Third Quarter Fiscal 2024 Results • Business Wire • 02/17/2024 12:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:03:00 PM
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model • Business Wire • 02/01/2024 02:20:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 09:04:23 PM
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s • Business Wire • 01/23/2024 02:20:00 PM
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial • Business Wire • 01/17/2024 02:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:54:29 PM
- Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s • Business Wire • 12/19/2023 02:20:00 PM
- IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 • Business Wire • 12/13/2023 02:30:00 PM
- IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials • Business Wire • 12/06/2023 01:30:00 PM
- IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives • Business Wire • 11/21/2023 01:30:00 PM
- IGC Pharma Reports Second Quarter Fiscal 2024 Results • Business Wire • 11/13/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:21:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/27/2023 08:38:17 PM
- IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy • Business Wire • 10/19/2023 07:30:00 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM